New StemExpress G-CSF Mobilized Leukopaks

StemExpress introduces G-CSF mobilized leukopaks to their extensive collection of blood-derived
cell products. After two years of working with their clients to develop a protocol in which institute
protocol standards were evaluated, a mobilized leukopak procedure was developed to bring a high-
quality product to clients demanding low granulocyte contamination, high cell viability, and an
increase in CD34 + cell frequencies.

According to Joe Andersen, PhD, Assistant Professor of Internal Medicine at UC Davis, “we worked
closely with StemExpress to obtain a product that had a low granulocyte and low hematocrit
population among the mononuclear cells. The final protocol for obtaining a high-quality mobilized
leukopak exceeded our expectations. Not only did we receive an exceptional product but we have
received all mobilized leukopaks from StemExpress within two weeks from the time of order.”

Human mobilized leukopaks provide a large quantity of mononuclear cells (MNCs) that contains a
rich source of hematopoietic stem cells as compared to traditional leukopaks. This allows
researchers greater reproducibility of experiments from a single donor (minimize donor-to- donor
variation), increase in scalability of experiments from a single product, and a decrease in same cell
variability by obtaining high yields of specific cell types.

Human mobilized peripheral blood leukopaks are collected from healthy IRB consented donors that
are negative for HIV, HBV and HCV from one of StemExpress’ Stem Cell Collection Centers.
Mobilized peripheral blood donors are injected with Granulocyte-Colony Stimulating Factor (G-
CSF), which stimulates the bone marrow to produce hematopoietic stem cells and mobilizes them
into the bloodstream, over a period of 3–5 days. Mobilized mononuclear cells are collected by a trained technician using the Spectra Optia ® Apheresis System one and two days post injection (1
bag collected per day).

Representative flow panel of fresh G-CSF mobilized leukopak. Enriched MNC population with low granulocytes (20.76%), high viability (97.65%), and high percentage of CD34 + cells (1.68%).

StemExpress’ donation centers adhere to Good Clinical Practice guidelines with IRB approved
informed consents and protocols providing the utmost care for their donors and the highest quality
of product to their customers. Each donation center employs a staff of certified apheresis
technicians and licensed medical physicians to ensure the care and wellbeing of their donors.
Donors undergo a thorough review of their historical and current medical history as well as
infectious disease screening every 90-days by a CLIA-certified laboratory.